Skip to main content

Table 4 Univariate and Multivariate analysis of prognostic factors for PBTC subgroup

From: Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution

Factors

n(%)

Univariate analysis

Multivariate analysis

mOS(95%CI)

χ2

p

B

HR(95%CI)

P

Age (years)

 ≤40

8 (3.9)

5.0 (0.0-25.7)

2.455

0.653

-

-

-

 41-50

19 (9.2)

8.2 (3.7-12.7)

  

-

-

-

 51-60

66 (31.9)

9.0 (5.4-12.6)

  

-

-

-

 61-70

78 (37.7)

8.2 (6.2-10.2)

  

-

-

-

 ≥71

36 (17.4)

8.3 (6.3-10.3)

  

-

-

-

Sex

 Male

115 (55.6)

7.0 (5.6-8.4)

1.589

0.208

-

-

-

 Female

92 (44.4)

9.7 (8.3-11.1)

  

-

-

-

Pain on the back and loin

 No

128 (61.8)

8.2 (6.0-10.4)

0.909

0.340

-

-

-

 Yes

79 (38.2)

8.7 (6.7-10.8)

  

-

-

-

Smoking history

 No

139 (67.1)

9.6 (8.0-11.2)

1.807

0.179

-

-

-

 Yes

68 (32.9)

7.0 (5.7-8.3)

  

-

-

-

Diabetes history

 No

119 (57.5)

9.0 (7.6-10.4)

0.864

0.353

-

-

-

 Yes

88 (42.5)

7.0 (5.0-9.0)

  

-

-

-

CA199(U/ml)

 <37

50 (24.2)

10.5 (6.1-14.9)

41.985

0.000

 

Reference

 

 ≥37and<200

54 (26.1)

12.0 (9.4-14.6)

  

0.056

1.058 (0.647-1.729)

0.823

 ≥200and<400

24 (11.6)

10.6 (8.0-13.2)

  

0.175

1.191 (0.642-2.211)

0.579

 ≥400and<800

28 (13.5)

7.6 (4.0-11.2)

  

0.757

2.131 (1.162-3.909)

0.015

 ≥800

51 (24.6)

5.0 (4.1-5.9)

  

0.813

2.255 (1.305-3.897)

0.004

CEA (ng/ml)

 <5

127 (61.4)

10.6 (8.8-12.4)

17.747

0.000

 

Reference

 

 ≥5

80 (38.6)

6.0 (5.4-6.7)

  

0.508

1.661 (1.152-2.397)

0.007

Albumin(g/L)

 <35

15 (7.2)

3.2 (0.0-7.8)

1.494

0.222

-

-

-

 ≥35

192 (92.8)

8.7 (7.1-10.3)

  

-

-

-

Total bilirubin (umol/l)

 <22

184 (88.9)

8.8 (7.3-10.3)

9.531

0.023

 

Reference

 

 ≥22and<100

21 (10.1)

5.4 (5.0-5.8)

  

0.620

1.858 (1.070-3.229)

0.028

 ≥100and<200

1 (0.5)

-

  

-1.082

0.339 (0.038-3.042)

0.334

 ≥200

1 (0.5)

-

  

1.780

5.927 (0.752-46.746)

0.091

Peripancreatic invasion

 No

46 (22.2)

13.4 (6.5-20.3)

10.891

0.000

 

Reference

 

 Yes

161 (77.8)

7.5 (6.1-8.9)

  

0.501

1.650 (1.077-2.529)

0.021

Degree of weight loss (kg)

 <5

123 (59.4)

9.0 (7.5-10.5)

0.567

0.452

-

-

-

 ≥5

84 (40.6)

7.0 (5.5-8.5)

  

-

-

-

NLRa

 <2

36 (17.4)

9.0 (5.8-12.2)

0.028

0.868

-

-

-

 ≥2

171 (82.6)

8.3 (6.7-9.9)

  

-

-

-

NLRb

 <3

99 (47.8)

9.0 (6.7-11.3)

0.000

0.993

-

-

-

 ≥3

108 (52.2)

8.2 (6.6-9.8)

  

-

-

-

NLRc

 <4

124 (59.9)

9.0 (7.3-10.7)

0.190

0.663

-

-

-

 ≥4

83 (40.1)

7.5 (5.8-9.2)

  

-

-

-

NLRd

 <5

180 (87.0)

9.0 (7.5-10.5)

5.990

0.014

 

Reference

 

 ≥5

27 (13.0)

3.4 (0.0-8.1)

  

0.500

1.649 (1.009-2.696)

0.046

Operative procedure

 Without operation

79 (38.2)

5.8 (4.9-6.7)

21.185

0.000

 

Reference

 

 Palliative operation

10 (4.8)

2.0 (0.7-3.3)

  

0.615

1.850 (0.817-4.189)

0.140

 Radical resection

118 (57.0)

11.0 (8.4-13.6)

  

0.153

1.166 (0.785-1.731)

0.447

Tumor size (cm)

 d<2

4 (1.9)

6.0 (0.0-14.1)

2.697

0.260

-

-

-

 2≤d<4

74 (35.7)

9.0 (6.1-11.9)

  

-

-

-

 d≥4

129 (62.3)

8.1 (6.6-9.6)

  

-

-

-

Hepatic metastasis

 No

41 (19.8)

10.0 (8.7-11.3)

30.997

0.000

 

Reference

 

 Yes

166 (80.2)

4.5 (2.4-6.6)

  

0.462

1.588 (0.966-2.610)

0.068

Lymph node metastasis

 No

141 (68.1)

7.1 (4.0-20.2)

0.091

0.763

-

-

-

 Yes

66 (31.9)

8.7 (7.2-10.2)

  

-

-

-

Number of distant organ metastasis

 0

119 (57.5)

11.0 (9.3-12.7)

36.997

0.000

 

Reference

 

 1

51 (24.6)

6.0 (4.5-7.5)

  

0.468

1.597 (1.009-2.527)

0.046

 ≥2

37 (17.9)

4.0 (2.4-5.6)

  

0.771

2.163 (1.268-3.690)

0.005

Adjuvant chemotherapy

 No

188 (90.8)

7.7 (6.2-9.2)

5.857

0.016

 

Reference

 

 Yes

19 (9.2)

17.5 (7.7-27.3)

  

-1.077

0.340 (0.182-0.638)

0.001

  1. NLR Neutrophil-lymphocyte ratio, HR Hazard ratio, CI Confidence interval, mOS Median overall survival
  2. p: Log Rank Mantel–Cox test; P: Cox proportional hazards model